Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing T… Read more
Tarsus Pharmaceuticals Inc (TARS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.054x
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has a cash flow conversion efficiency ratio of 0.054x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($18.26 Million) by net assets ($335.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tarsus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Tarsus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tarsus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
L&F Co. Ltd
KQ:066970
|
0.167x |
|
Immunovant Inc
NASDAQ:IMVT
|
-0.094x |
|
TISCO Financial Group Public Company Limited
BK:TISCO
|
0.075x |
|
Barito Pacific Tbk
JK:BRPT
|
0.043x |
|
Carl Zeiss Meditec AG
PINK:CZMWF
|
0.092x |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SHE:000636
|
0.007x |
|
Dorma Kaba Holding AG
SW:DOKA
|
0.659x |
|
Sona BLW Precision Forgings Limited
NSE:SONACOMS
|
0.037x |
Annual Cash Flow Conversion Efficiency for Tarsus Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $224.53 Million | $-83.03 Million | -0.370x | +38.00% |
| 2023-12-31 | $196.99 Million | $-117.49 Million | -0.596x | -134.66% |
| 2022-12-31 | $192.90 Million | $-49.03 Million | -0.254x | -1230.69% |
| 2021-12-31 | $166.73 Million | $3.75 Million | 0.022x | +117.65% |
| 2020-12-31 | $165.98 Million | $-21.14 Million | -0.127x | -120.82% |
| 2019-12-31 | $-6.00 Million | $-3.67 Million | 0.612x | -29.99% |
| 2018-12-31 | $-1.35 Million | $-1.18 Million | 0.874x | -- |